Q: Celgene appears to be stumbling higher, presumably towards the value assigned to it from the Bristol Myers merger. In past months, you previously suggested holding on; is that still your view? Also, can you suggest a source for information on the tax treatment from the merger for Canadian taxpayers who hold Celgene? Thanks,
Q: Any idea why TH has been so weak lately. I know sales have been short of expectations for their new life saving drug but they are still rising slowly. Also their older drug Egrifta may have some benefits for people with NAFLD/NASH. Balance sheet is good.
Q: Could I get your thoughts on how HHL might behave in a recession. I understand Healthcare as a sector would be a Defensive sector however I also understand 5i is not to crazy about the cover call aspect, believing it would not protect again the down side. So how would HHL behave? Would the price fall greater than the average defensive share price, or would investors still consider it a defensive play and hold steady the price. Or would the cover call aspect cease to work and the dividends reduce? If it's more an impact on the dividends, is there a way of telling how much the
cover calling is adding to the dividends and therefore what dividends could be expected in times of a recession. Thanks
Q: Theratechnologies was at $9.35 on Feb 28th and it closed on Mar 15th at $6.99. The recent press releases all seem favorable to me. Why is this stock down so dramatically?
Q: To add to what Steven comment today on the Company. I respect M. Goodman view on the long term goals of the company. His analogy for is "grandchildren" and stockholders would make sense if at the very least a dividend would be paid for waiting.
This would a small way to compensate to the shareholders while we are supporting the company.
Q: High volume at the close. My guess is insiders did the buying, if so how many days before they have to disclose ?
Also I noticed that for my last 2 questions I did not receive the answer by email but saw the answer on your site. Has something changed ?
Thanks for your help.
Q: In response to a question about a subscriber's portfolio you said “KO and JNJ we would consider less attractive for various reasons. We might add VZ and PFE instead.”. I am holding JNJ in a non-registered account with a cost base of $58.36/share. JNJ is 2.5% of a diversified portfolio. Is it still worth making the switch for PFE? Over the years, JNJ seemed to be a much better managed company than PFE. What has changed?
Q: I have very little in the health care industry, I only own GUD at 1.5% of my portfolio. I am thinking of selling GUD and buying ZUH at say 2.5% of my portfolio. Your thoughts please. Or would you suggest some other health ETF?
Q: In response to a recent question about GUD, you mentioned that "there is an unhappy shareholder and board member who wants some changes made at the company". Could you please provide more detail about why he/she is unhappy and what changes they would like to be made? Thank you.
Q: Not a question just a statement. Here is a reminder for us long term holders of Knight Therapeutics on what the investment horizon may be.
"For investors, if their investment horizon is not their grandchildren, we are not the right company for them. Paladin had 19 years of record revenues but for 12 of those years, our stock was flat. It took us 19 years to become an overnight success." - Jonathan Ross Goodman